FDA Clearance Tracker · P010029-S001
NUXFLEXXA (SODIUM HYALURONATE)
Last checked: Nov 20, 2026Latest source record: Feb 27, 2006 (this decision)Source: openFDAMethods & limitations
Decided
Feb 27, 2006
Approved
Time to decision
410 days
Received Jan 13, 2005. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P010029-S001
- Device name
- NUXFLEXXA (SODIUM HYALURONATE)
- Applicant
- Ferring Pharmaceuticals, Inc.
- Applicant location
- Parsippany, NJ
- Received
- Jan 13, 2005
- Decided
- Feb 27, 2006
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Original approval
- P010029
Device type
- Device type
- Acid, hyaluronic, intraarticular (MOZ)
- Device class
- Class III
- Specialty
- Orthopedic Surgery
FDA's approval statement
As written in FDA's record.
APPROVAL FOR 1) CHANGING THE STORAGE CONDITIONS SPECIFIED IN THE PRODUCT LABELING FROM, ?STORE IN A COLD DARK PLACE [2 ? 8 DEGREES C (36-46 DEGREES F)]. PROTECT FROM LIGHT. DO NOT FREEZE?. 2) CHANGE THE SPECIFIED SHELF LIFE TIME IN THE LABELING FORM 3 YEARS (AT REFRIGERATED TEMPERATURES) TO 12 MONTHS. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME EUFLEXXA AND IS INDICATED FOR THE TREATMENT OF PAIN IN OSTEOARTHRITIS (OA) OF THE KNEE IN PATIENTS WHO HAVE FAILED TO RESPOND ADEQUATELY TO CONSERVATIVE NON-PHARMACOLOGIC THERAPY AND TO SIMPLE ANALGESICS (E.G., ACETAMINOPHEN.)
Source documents
Other decisions for Ferring Pharmaceuticals, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.